Yi Shen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Yi Shen has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Li Yang
Department of Internal Medicine, Brody School of Medicine, East Carolina University, Greenville, NC 27834, USA
2 shared publications - Dan Zhou
Department of Gastroenterology and Hepatology and Laboratory of Gastrointestinal Cancer and Liver Disease, West China Hospital, Sichuan University, Chengdu, China
1 shared publication - Dan Zhou
Department of Gastroenterology and Hepatology, and Laboratory of Gastrointestinal Cancer and Liver Disease West China Hospital, Sichuan University Chengdu Sichuan Province China
1 shared publication - Fan Yang
Department of Gastroenterology and Hepatology and Laboratory of Gastrointestinal Cancer and Liver Disease, West China Hospital, Sichuan University, Chengdu, China
1 shared publication - Jie Sun
Department of Gastroenterology and Hepatology and Laboratory of Gastrointestinal Cancer and Liver Disease, West China Hospital, Sichuan University, Chengdu, China
1 shared publication - LeYu Zhou
Department of Gastroenterology and Hepatology and Laboratory of Gastrointestinal Cancer and Liver Disease, West China Hospital Sichuan University Chengdu Sichuan Province China
1 shared publication
Latest Publications
- 13 July 2026
- Published by Wiley in Liver International
- Vol. 46 (8) , e70796
Reply to ‘Biopsy Before Autoimmune Hepatitis Withdrawal: The Estimand Matters’
- 13 July 2026
- Published by Wiley in Liver International
- Vol. 46 (8) , e70796
Reply to ‘Biopsy Before Autoimmune Hepatitis Withdrawal: The Estimand Matters’
- 4 January 2026
- Published by Springer Nature in Hepatology International
- Vol. 20 (2) , 342-352
Genuine acute autoimmune hepatitis has better therapeutic response and prognosis
Background and aim Heterogeneous diagnostic criteria for acute autoimmune hepatitis (AIH) across studies hinder the characterization of genuine acute AIH. We developed stringent and multidimensional criteria to distinguish acute, acute-on-chronic, and chronic autoimmune hepatitis (A-AIH, AC-AIH, and C-AIH), aiming to elucidate their clinical profiles. Methods We consecutively enrolled patients diagnosed with definite AIH between 2012 and 2024. All patients were stratified using stringent criteria encompassing onset time (A-AIH: < 6 months), acute presentation (total bilirubin (TB) ≥ 5 mg/dL or alanine aminotransferase (ALT)/aspartate aminotransferase (AST) ≥ 10 × upper limits of normal (ULN)), imaging evidence of cirrhosis, and histological fibrosis stage (A-AIH: fibrosis stage ≤ 1). Clinical features and treatment responses were compared across the three groups. Results Among 235 patients, 10.6% were classified as A-AIH, 57.9% as AC-AIH, and 31.5% as C-AIH, with a median follow-up of 51.9 (IQR 21.8–78.8) months. The cumulative full biochemical remission (FBR) rate was 92.0% in A-AIH, 75.7% in AC-AIH, and 59.5% in C-AIH (p = 0.003). The median FBR times were 2.9, 5.5, and 14.5 months, respectively (p = 0.002). Liver-related mortality rates were 0%, 8.8%, and 16.2% across the three groups (p = 0.021). Cirrhosis and albumin (ALB) levels were independent predictors of FBR, and ALB was also independently associated with liver-related death. Conclusion Patients with A-AIH achieved the highest cumulative FBR rate, whereas those with C-AIH had the poorest treatment response and the highest liver-related mortality. Graphical abstract
- 4 January 2026
- Published by Springer Nature in Hepatology International
- Vol. 20 (2) , 342-352
Genuine acute autoimmune hepatitis has better therapeutic response and prognosis
Background and aim Heterogeneous diagnostic criteria for acute autoimmune hepatitis (AIH) across studies hinder the characterization of genuine acute AIH. We developed stringent and multidimensional criteria to distinguish acute, acute-on-chronic, and chronic autoimmune hepatitis (A-AIH, AC-AIH, and C-AIH), aiming to elucidate their clinical profiles. Methods We consecutively enrolled patients diagnosed with definite AIH between 2012 and 2024. All patients were stratified using stringent criteria encompassing onset time (A-AIH: < 6 months), acute presentation (total bilirubin (TB) ≥ 5 mg/dL or alanine aminotransferase (ALT)/aspartate aminotransferase (AST) ≥ 10 × upper limits of normal (ULN)), imaging evidence of cirrhosis, and histological fibrosis stage (A-AIH: fibrosis stage ≤ 1). Clinical features and treatment responses were compared across the three groups. Results Among 235 patients, 10.6% were classified as A-AIH, 57.9% as AC-AIH, and 31.5% as C-AIH, with a median follow-up of 51.9 (IQR 21.8–78.8) months. The cumulative full biochemical remission (FBR) rate was 92.0% in A-AIH, 75.7% in AC-AIH, and 59.5% in C-AIH (p = 0.003). The median FBR times were 2.9, 5.5, and 14.5 months, respectively (p = 0.002). Liver-related mortality rates were 0%, 8.8%, and 16.2% across the three groups (p = 0.021). Cirrhosis and albumin (ALB) levels were independent predictors of FBR, and ALB was also independently associated with liver-related death. Conclusion Patients with A-AIH achieved the highest cumulative FBR rate, whereas those with C-AIH had the poorest treatment response and the highest liver-related mortality. Graphical abstract